Primary Prophylaxis against Pneumocystis carinii Pneumonia

Richard Tarabey; Margriet M.e. Schneider; Andy I.m. Hoepelman; Jan C.c. Borleffs

doi:10.1056/NEJM199305203282019

Primary Prophylaxis against Pneumocystis carinii Pneumonia

Richard Tarabey
, Margriet M.e. Schneider
, Andy I.m. Hoepelman
, Jan C.c. Borleffs

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

To the Editor: Schneider et al. (Dec. 24 issue)¹ concluded that a single dose (either 480 mg or 960 mg) of trimethoprim-sulfamethoxazole once a day is superior to aerosolized pentamidine once a month for the prevention of Pneumocystis carinii pneumonia (PCP) in patients with human immunodeficiency virus (HIV) infection. All the patients had comparable base-line CD4 cell counts. The authors do not report CD4 cell counts for the follow-up period. Zidovudine,²–⁴ which was used by many patients in this study, may increase the CD4 cell count and therefore diminish the risk of PCP. In the three groups of patients,…

Original language	English
Number of pages	1
Journal	New England Journal of Medicine
Volume	328
Issue number	20
DOIs	https://doi.org/10.1056/NEJM199305203282019
Publication status	Published - 20 May 1993

Access to Document

10.1056/NEJM199305203282019

Cite this

@article{8ce0cbb285e149d587f0d2c87cc0eb1e,

title = "Primary Prophylaxis against Pneumocystis carinii Pneumonia",

abstract = "To the Editor: Schneider et al. (Dec. 24 issue)1 concluded that a single dose (either 480 mg or 960 mg) of trimethoprim-sulfamethoxazole once a day is superior to aerosolized pentamidine once a month for the prevention of Pneumocystis carinii pneumonia (PCP) in patients with human immunodeficiency virus (HIV) infection. All the patients had comparable base-line CD4 cell counts. The authors do not report CD4 cell counts for the follow-up period. Zidovudine,2–4 which was used by many patients in this study, may increase the CD4 cell count and therefore diminish the risk of PCP. In the three groups of patients,…",

author = "Richard Tarabey and Schneider, \{Margriet M.e.\} and Hoepelman, \{Andy I.m.\} and Borleffs, \{Jan C.c.\}",

year = "1993",

month = may,

day = "20",

doi = "10.1056/NEJM199305203282019",

language = "English",

volume = "328",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "20",

}

TY - JOUR

T1 - Primary Prophylaxis against Pneumocystis carinii Pneumonia

AU - Tarabey, Richard

AU - Schneider, Margriet M.e.

AU - Hoepelman, Andy I.m.

AU - Borleffs, Jan C.c.

PY - 1993/5/20

Y1 - 1993/5/20

N2 - To the Editor: Schneider et al. (Dec. 24 issue)1 concluded that a single dose (either 480 mg or 960 mg) of trimethoprim-sulfamethoxazole once a day is superior to aerosolized pentamidine once a month for the prevention of Pneumocystis carinii pneumonia (PCP) in patients with human immunodeficiency virus (HIV) infection. All the patients had comparable base-line CD4 cell counts. The authors do not report CD4 cell counts for the follow-up period. Zidovudine,2–4 which was used by many patients in this study, may increase the CD4 cell count and therefore diminish the risk of PCP. In the three groups of patients,…

AB - To the Editor: Schneider et al. (Dec. 24 issue)1 concluded that a single dose (either 480 mg or 960 mg) of trimethoprim-sulfamethoxazole once a day is superior to aerosolized pentamidine once a month for the prevention of Pneumocystis carinii pneumonia (PCP) in patients with human immunodeficiency virus (HIV) infection. All the patients had comparable base-line CD4 cell counts. The authors do not report CD4 cell counts for the follow-up period. Zidovudine,2–4 which was used by many patients in this study, may increase the CD4 cell count and therefore diminish the risk of PCP. In the three groups of patients,…

UR - https://www.scopus.com/pages/publications/0027312020

U2 - 10.1056/NEJM199305203282019

DO - 10.1056/NEJM199305203282019

M3 - Comment/Letter to the editor

C2 - 8097561

AN - SCOPUS:0027312020

SN - 0028-4793

VL - 328

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 20

ER -

Primary Prophylaxis against Pneumocystis carinii Pneumonia

Abstract

Access to Document

Other files and links

Fingerprint

Cite this